Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by awol1on Feb 08, 2013 4:18pm
292 Views
Post# 20961151

brigus mentioned- strong buy

brigus mentioned- strong buy

https://etfdailynews.com/2013/02/08/eric-winmill-money-stimulus-marathon-good-for-gold-price-gdx-aem-brd-gg-ar-er-sas-yng-ssl/       mentioned a merger with St Andrew Goldfields (T-SAS)...               portion related to Brigus below....                                    

TGR: And Brigus?

EW: Brigus has the Black Fox mine in Timmins. It is an open-pit and underground mine that Brigus has done a great job on, ramping up production. The company recently brought on Daniel Racine as chief operating officer, and he has just assumed the role of president. Racine has worked at Agnico-Eagle Mines Ltd. (NYSE:AEM) for many years. Brigus has put together a really strong team and the result can be seen in its latest production results. Cash costs are declining and production is increasing. Longer term, Brigus is drilling off its Grey Fox property, not far from Black Fox, and hopes to bring it into production in early 2015.

TGR: Other pundits in this space believe that a business combination of Brigus and St. Andrew makes sense. Do you agree?

EW: Certainly, when you look at the land map of the two companies’ assets, there could be operational synergies. But I really could not speak to any of the particulars of that kind of a combination.

TGR: What are the biggest catalysts for Brigus in 2013?

EW: We should see the company’s financial results for Q4/12 by the end of March.

We anticipate a feasibility study of Grey Fox in the latter half of 2013. The company is talking about 2013 production of 90–100 Koz, up from 77 Koz in 2012. It could be an exciting year for Brigus.

TGR: A couple of years ago Brigus was in turnaround. Is that process complete?

EW: The company has been growing production at Black Fox and the latest results suggest that the operation is hitting its stride.

TGR: Can you give our readers a reason or two to be hopeful in 2013, after a difficult 2012?

EW: I think the industry as a whole has gotten the message loud and clear that it is all about a renewed focus on smart projects and efficient capital allocation, not just growth for growth’s sake. In addition, the industry trend toward reporting all-in sustaining cash costs should help investors make better decisions about which companies are really adding cash to the balance sheet.

TGR: Eric, thank you for your time and your insights.

Eric Winmill joined Casimir Capital in 2012 as a mining analyst in the Equity Research Department. Winmill has 14 years of capital markets’ experience, primarily in the evaluation and analysis of precious and base metal projects around the globe. Most recently he worked in mining equity research at National Bank Financial and at Wellington West Capital Markets. Prior to that, Winmill was a vice president at Regent Mercantile Bancorp, a private resource-based merchant bank. Winmill holds a Bachelor of Commerce from McGill University and a Master in Finance from Rotman School of Management, and is a CFA Charterholder.

Bullboard Posts